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Abstract  Intravenous  thrombolysis  (IVT)  with  alteplase  remains  the  standard  treatment  for
acute ischemic  stroke.  Although  IVT  can  be  started  up  to  4.5  hours  after  symptoms’  onset,  it  is
all the  more  effective  and  safe  when  started  early.  It  allows  a  10%  absolute  reduction  in  the  risk
of handicap  or  death  at  3  months,  despite  a  2—7%  risk  of  symptomatic  intracranial  hemorrhage.
Current research  efforts  involve  ﬁrstly  trying  to  treat  a  larger  proportion  of  patients  by  over-
coming some  of  the  contraindications  to  IVT  and  secondly  assessing  combined  or  alternativeThrombectomy treatments  to  achieve  a  higher  early  recanalization  rate.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Intravenous  thrombolysis  (IVT)  for  acute  ischemic  stroke  (AIS)  is  intended  to  produce
early  arterial  recanalization,  allowing  reperfusion  of  the  ischemic  penumbral  tissue,  to
avoid  its  progression  to  infarction  [1].  IVT  with  alteplase  remains  the  standard  treatment
within  the  4.5  hours  window  after  symptoms’  onset  [2].
Pivotal clinical trials
The  clinical  efﬁcacy  of  IVT  with  alteplase  was  demonstrated  as  early  as  1995  in  the  NINDS
randomized  controlled  trial,  which  compared  IVT  to  placebo  within  3  hours  after  symptoms’
onset  [3].  The  diagnosis  of  AIS  was  based  on  the  results  of  a  non-contrast  brain  CT.  Within
the  3-hours’  time  hours’  time  window,  IVT  allowed  a  50%  relative  increase  in  the  proportion
of  patients  without  disability  at  3  months  (modiﬁed  Rankin  scale  [mRS]  ≤  1):  39%  vs.  26%,
i.e.  a  13%  absolute  increase  as  compared  to  placebo  (number  needed  to  treat  =  8).  The
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Despite  major  advances,  less  than  10%  of  all  ischemic130  
isk  of  symptomatic  intracranial  hemorrhage  (sICH)  was  6%  in
he  ﬁrst  36  hours  after  IVT  (compared  to  0.6%  in  the  placebo
rm).  Three-month  mortality  rates  did  not  differ  between
he  two  arms.
In  2008,  the  ECASS  3  randomized  controlled  trial  demon-
trated  the  clinical  efﬁcacy  of  IVT  within  the  3—4.5  hour
ime  window  [4].  Compared  to  placebo,  IVT  allowed  a  16%
elative  increase  in  the  proportion  of  patients  without  dis-
bility  (mRS  ≤  1)  at  3  months:  52%  vs.  45%  (absolute  increase
%,  number  needed  to  treat  =  14).  The  rate  of  sICH  was  8%
sing  the  same  deﬁnition  as  in  the  NINDS  study  and  mortality
ates  were  similar  in  both  arms.
unctional prognosis, hemorrhagic
ransformation and mortality rates in
linical registries
ecause  patients  included  in  clinical  trials  might  differ  from
hose  seen  in  everyday  practice,  the  SITS  (Safe  Implemen-
ation  of  Thrombolysis  in  Stroke)  European  registries  have
een  set  up  since  2002  to  assess  the  outcome  of  patients
reated  by  IVT  for  AIS.  Three  months  after  AIS,  40  to  45%
f  patients  were  free  of  any  handicap  (mRS  ≤  1)  and  55  to
0%  were  independent  in  activities  of  daily  living  (mRS  ≤  2)
5,6].
Independent  predictors  of  poor  functional  outcome
mRS  >  2)  at  3  months  despite  IVT  are  age,  clinical  severity
t  baseline  (NIHSS  score),  blood  glucose  level  on  admission,
nset-to-treatment  time,  pre-existing  handicap,  proximal
rtery  occlusion,  initial  lesion  volume  and  lack  of  early
ecanalization  [7,8].
In  the  SITS  registries,  the  rate  of  sICH  after  IVT  was  7%
ccording  to  the  NINDS  study  deﬁnition  and  2  to  5%  using
lternative,  more  conservative  deﬁnitions  requiring  a  proba-
le  causal  relationship  between  the  hemorrhage  and  clinical
eterioration  [5].  Predictors  of  sICH  are  age,  baseline  NIHSS
core,  blood  glucose  level  on  admission,  blood  pressure,
nset-to-treatment  time,  proximal  artery  occlusion  and  ini-
ial  lesion  volume  [9].  Overly  late  recanalisation  may  also  be
 predisposing  factor,  although  this  is  still  debated  [10,11].
Three-month  mortality  in  the  SITS  registries  was  12%,  vs.
8%  in  randomized  trials.
atients aged over 80
he  ﬁndings  described  in  the  previous  paragraphs  led  to
arket  authorization  being  granted  for  IVT  with  alteplase
Activase®)  within  4.5  hours  after  symptoms’  onset  of  AIS,
ut  only  in  patients  under  80  years  old.  Less  than  100  elderly
atients  were  included  in  the  randomized  trials  comparing
VT  to  placebo  before  publication  of  the  IST-3  study  in  2012
12,13].  IST-3  was  an  open,  randomized  study  intended  to
ompare  IVT  with  control  treatment  (mostly  aspirin)  in  the
—6  hour  time  window  [12].  Although  IST-3  failed  to  demon-
trate  the  superiority  of  IVT  regarding  the  primary  end  point
absent  or  mild  functional  disability  at  6  months),  proba-
ly  because  the  treatment  window  was  too  wide,  this  is  an
mportant  study  as  it  included  over  1600  patients  who  were
0  years  old  or  older,  which  represent  half  of  all  enrolled
s
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atients.  This  study  established  that  the  clinical  efﬁcacy  of
VT  did  not  decrease  with  age  in  the  0—3  hour  time  win-
ow.  This  result  was  conﬁrmed  in  a meta-analysis  showing
hat  IVT  allowed  a  10%  absolute  increase  in  the  proportion
f  patients  who  were  independent  in  activities  of  daily  liv-
ng  (mRS  ≤  2)  at  3  or  6  months.  The  effect  size  was  similar
n  patients  under  80  years  old  (mRS  ≤  2:  50%  vs.  40%  in  the
lacebo  arm)  and  in  those  ≥  80  years  old  (mRS  ≤  2:  29%  vs.
9%  in  the  placebo  arm)  [13].
Regarding  the  3—4.5  hour  time  window,  published  data
re  less  clear-cut  for  older  patients.  Although  an  individual
atient  data  meta-analysis  from  9  randomized  placebo-
ontrolled  trials  suggested  that  IVT  had  a similar  effect  size
n  patients  under  80  years  old  (mRS  ≤  1:  OR  1.26  CI95%:
.04—1.54)  and  ≥  80  years  old  (mRS  ≤  1:  OR  1.36  CI95%:
.87—2.14),  this  meta-analysis  was  inadequately  powered
o  formally  conﬁrm  the  clinical  efﬁcacy  of  IVT  between  3
nd  4.5  hours  in  elderly  patients  [14].  Despite  the  fact  that
VT  is  not  currently  licensed  for  use  in  AIS  patients  ≥  80
ears  old,  age  is  not  considered  to  be  an  exclusion  crite-
ion  for  IVT  in  most  stroke  units,  in  accordance  with  French
nd  international  guidelines  [15—17].
he importance of early treatment
lthough  IVT  may  be  started  up  to  4.5  hours  after  symptoms’
nset,  several  meta-analyses  and  registries  have  shown  that
t  is  all  the  more  effective  when  administered  early  [18,19].
he  ‘‘Get  With  The  Guidelines—Stroke  Program’’  North
merican  registry  showed  that  faster  onset-to-treatment
ime,  per  15  minutes  increment,  was  associated  with  a  4%
ncrease  in  achievement  of  independent  ambulation  at  hos-
ital  discharge,  a 4%  decrease  in  the  risk  of  sICH,  and  a  4%
eduction  in  the  risk  of  death  [18]. These  results  are  consis-
ent  with  the  pathophysiology  of  AIS,  as  ﬁrstly  the  conversion
f  the  penumbral  tissue  into  necrotic  core  depends  directly
n  the  duration  of  severe  hypoperfusion  and  secondly  the
robability  to  achieve  arterial  recanalisation  increases  with
arlier  obstruction  as  the  thrombus  is  potentially  less  orga-
ized  [20].
The  median  onset-to-treatment  time  is  approximately
40  minutes  in  industrialized  countries  [6,18].  Further
educing  this  time  would  help  to  improve  the  prognosis
f  patients  who  are  treated,  but  also  allow  more  patients
o  be  treated  [21]. Optimizing  each  stage  in  AIS  manage-
ent  is  therefore  a  major  objective,  requiring  education
f  the  general  public  (through  national  campaigns)  and
urther  reduction  of  the  pre-hospital  and  hospital  patient
anagement  times.  Speciﬁcally,  although  the  recommended
oor-to-needle  time  is  under  60  minutes,  several  centers
ave  reduced  it  to  approximately  20  minutes  using  speciﬁc
rganization  [2,22,23].
uture prospects: treating more patientstrokes  are  treated  by  IVT  in  industrialized  countries,  mostly
ecause  they  arrive  too  late  in  hospital  [24].  Several  strate-
ies  are  currently  being  assessed  in  order  to  increase  the
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proportion  of  patients  who  are  treated.  Some  of  the  many
contraindications  of  IVT  for  AIS  are  now  deemed  to  be
obsolete  or  minor  thanks  to  observational  studies  and  ran-
domized  data  showing  that,  in  several  situations,  off-label
IVT  is  not  associated  with  poorer  clinical  outcome  [14,25].
These  ﬁndings  relate  to  age,  epileptic  seizures,  improving  or
minor  neurological  deﬁcit,  or  conversely  very  severe  neuro-
logical  deﬁcit  [14].  Although  lack  of  visible  arterial  occlusion
is  considered  by  some  groups  to  be  a  non-indication  for  IVT,
no  arterial  occlusion  was  deemed  necessary  in  the  pivotal
studies,  and  observational  data  suggest  that  these  patients
may  also  beneﬁt  from  IVT  [26].
Extending  the  treatment  window  for  IVT  beyond  4.5  hours
has  been  a  long-standing  goal.  However,  all  of  the  random-
ized  trials  which  have  assessed  IVT  beyond  4.5  hours  have
been  negative  or  neutral  so  far  [14].  Perfusion-weighted
imaging  may  help  to  identify  patients  with  a  persistent
ischemic  penumbra  beyond  the  4.5  hour  time  window,  and
therefore  to  select  potentially  good  candidates  for  late
IVT  [10].  This  approach  is  currently  being  assessed  in  a
randomized  trial  based  on  the  existence  of  an  MRI  diffusion-
perfusion  mismatch  (ECASS  4-Extend  study).  Brain  MRI  may
also  allow  some  of  the  wake-up  or  unknown  time  onset
AIS  (which  represents  approximately  15%  of  all  AIS)  to  be
treated  by  IVT  [27].  Diffusion-FLAIR  mismatch  (i.e.  AIS  vis-
ible  on  diffusion  weighted  imaging  but  not  yet  on  FLAIR)
has  positive  and  negative  predictive  values  >  90%  to  deter-
mine  that  symptoms  are  recent  (less  than  3  hours  or  even
less  than  4.5  hours)  [28,29].  One  randomized  trial  compar-
ing  IVT  to  placebo  in  patients  suffering  wake-up  stroke  with
a  diffusion-FLAIR  mismatch  is  currently  ongoing  (Wake-up
study),  following  encouraging  observational  ﬁndings  [30].
Telemedicine  (telestroke)  is  bringing  the  expertise  of
stroke  physicians  and  neuroradiologists  to  help  emergency
department  physicians  to  start  IVT  in  hospitals  lacking  a
dedicated  stroke  unit  [31].
An  original  approach  has  been  recently  proposed  by  two
German  groups,  which  involves  ‘‘bringing  the  hospital  to  the
patient’’  via  a  mobile  stroke  unit  (MSU),  in  order  to  start
IVT  directly  at  the  site  of  the  AIS  [21,32].  The  MSU  is  a
dedicated  ambulance  equipped  with  a  CT,  a  point-of-care
laboratory,  a  telemedicine  solution  and  involving  an  onboard
stroke  neurologist  and  radiology  technician.  This  strategy
has  been  assessed  on  a  randomized  basis  in  a  semi-rural  set-
ting  and  then  in  Berlin  and  has  allowed  a  25-min  median
onset-to-IVT  time  reduction  compared  to  usual  care  [21].
Moreover,  the  Berlin  (PHANTOM-S)  study  showed  that  the
MSU  helped  increase  the  proportion  of  patients  treated  with
IVT  for  AIS  by  over  50%.  Several  clinical  trials  are  now  ongo-
ing  in  Europe  and  the  United  States  in  order  to  demonstrate
that  this  approach  reduces  long-term  disability.
Future prospects: improving the
beneﬁt/risk balance of IVT
Although  unquestionable,  the  efﬁcacy  of  IVT  remains
limited,  as  almost  50%  of  treated  patients  still  have  sig-
niﬁcant  functional  disability  at  3  months  [6].  The  arterial
recanalisation  rate  after  IVT  is  no  more  than  50%  [33],  and
additional  endovascular  treatment  (‘‘stentrievers’’)  may  be
d
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 key  option.  However,  whilst  combined  treatment  with  IVT
nd  endovascular  approach  (bridging  therapy)  allows  high
ecanalization  rates,  no  randomized  trial  have  yet  demon-
trated  bridging  therapy  to  be  superior  to  IVT  alone  in
erms  of  long-term  disability  [34,35]. Subgroup  analyses
rom  the  IMS-3  trial  suggest  that  trials  assessing  bridging
herapy  should  focus  on  patients  with  severe  neurological
eﬁcit,  proximal  arterial  occlusion  and  treated  very  early
34]. Thanks  to  dedicated  scores,  identifying  on  hospital
dmission  patients  likely  to  have  poor  long-term  functional
rognosis  despite  IVT  is  feasible  and  could  help  selecting  the
est  candidates  to  assess  bridging  therapy  [7,8].  Several  ran-
omized  trials  of  bridging  therapy  are  ongoing  (MR  CLEAN,
HRACE,  SWIFT  PRIME,  BASICS  trial,  etc.).
Apart  from  endovascular  strategies,  three  main
pproaches  have  been  proposed  to  improve  the  effec-
iveness  of  IVT:  reducing  the  onset-to-treatment  time
which  would  also  reduce  the  risk  of  sICH),  using  next-
eneration  thrombolytics  instead  of  alteplase,  or  carrying
ut  sonothrombolysis.
Two  recent  thrombolytics,  desmoteplase  and
enecteplase,  have  theoretical  advantages  over  alteplase,
articularly  greater  afﬁnity  for  ﬁbrin,  reduced  neurotoxicity
nd  administration  as  a  single  one-minute  bolus  rather  than
 one-hour  infusion  [36,37]. Unfortunately,  desmoteplase
as  not  been  shown  to  be  superior  to  placebo  in  the
—9  hours  time  window  (DIAS  3  trial,  intention-to-treat
nalysis).  Tenecteplase,  however,  has  been  shown  to  be
uperior  to  alteplase  in  a  phase  IIb  randomized  study  in
he  0—6  hours  time  window  [37]. This  trial  involved  highly
elected  patients  with  intracranial  artery  occlusion  and
ersistent  ischemic  penumbra,  both  of  which  were  deter-
ined  on  CT.  Administration  of  tenecteplase  was  associated
ith  a  signiﬁcant  short-term  and  3-month  clinical  beneﬁt
ompared  to  alteplase,  and  a  non-signiﬁcant  trend  towards
ower  risk  of  sICH.  However,  this  study  should  be  considered
s  preliminary  because  of  the  small  number  of  patients  and
ifferent  proximal  middle  cerebral  artery  occlusion  rates
etween  the  tenecteplase  and  alteplase  arms.  Several
linical  trials  comparing  tenecteplase  and  alteplase  are
ngoing.
Sonothrombolysis  has  been  proposed  for  patients  with  a
iddle  cerebral  artery  occlusion.  It  involves  applying  low
ntensity,  high  frequency  ultrasounds  to  the  occlusion  site
ver  2  hours  via  a  transcranial  Doppler  to  increase  the  throm-
olytic  effect,  by  allowing  better  exposure  of  the  thrombus
o  alteplase.  One  phase  II  randomized  study  has  shown
onothrombolysis  to  be  superior  to  IVT  alone  in  terms  of  com-
lete  recanalization  rates  (assessed  by  transcranial  Doppler
ltrasonography)  two  hours  after  starting  IVT  [38]. A  non-
igniﬁcant  trend  in  favor  of  sonothrombolysis  was  observed
or  3-month  functional  outcome.  No  signiﬁcant  difference
as  shown  between  the  two  groups  in  terms  of  sICH.  One
ouble-blind,  phase  III  randomized  controlled  trail  is  ongoing
CLOTBUST-ER).
Reducing  the  risk  of  IVT-related  hemorrhage  would  also
mprove  the  beneﬁt/risk  balance  for  this  therapy.  The
nchanted  randomized  trial  is  currently  comparing  the  usual
ose  of  alteplase  (0.9  mg/kg)  to  a  lower  dose  (0.6  mg/kg,
hich  is  used  routinely  in  Japan)  in  order  to  establish
hether  the  lower  dose  reduces  the  risk  of  sICH  without
educing  the  effectiveness  of  IVT.
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n  conclusion,  IVT  with  alteplase  within  4.5  hours  after  AIS
nset  is  currently  the  only  treatment  proven  to  be  clin-
cally  effective  and  which  is  currently  approved  for  the
anagement  of  this  condition.  It  allows  an  approximately
0%  absolute  reduction  in  the  risk  of  disability  or  death  at
 months,  despite  a  2—7%  risk  of  sICH,  depending  on  the
eﬁnitions  used.  The  contribution  of  additional  endovascu-
ar  therapy  or  next-generation  thrombolytics  will  need  to  be
etermined  in  randomized  trials  using  IVT  with  alteplase  as
he  control  group,  and  long-term  functional  disability  as  the
rimary  outcome.
TAKE-HOME  MESSAGES
• Intravenous  thrombolysis  with  alteplase  is  currently
the  standard  treatment  for  acute  ischemic  stroke.
• It  allows  a  10%  absolute  reduction  in  the  risk  of
disability  or  death  at  3  months.
• The  earlier  intravenous  thrombolysis  is  started,  the
more  effective  it  will  be.
• It  has  clearly  been  shown  to  be  beneﬁcial  under  the
age  of  80  years  old  within  4.5  hours  after  symptoms’
onset.
• After  the  age  of  80  years  old,  intravenous
thrombolysis  is  currently  given  off-label  in  France,
as  randomized  control  trials  did  not  show  reduced
beneﬁts  of  treatment  based  on  age.
• Approximately  55%  of  all  patients  treated  with
intravenous  thrombolysis  are  independent  in
activities  of  daily  living  3  months  after  the  ischemic
stroke.
• The  incidence  of  symptomatic  intracranial
hemorrhage  after  intravenous  thrombolysis  is  2
to  7%,  depending  on  the  deﬁnitions  used.
• Bridging  therapy  (intravenous  thrombolysis  followed
by  an  endovascular  procedure)  may  be  superior
to  intravenous  thrombolysis  alone  in  patients  with
proximal  arterial  obstruction  treated  early,  although
this  point  needs  to  be  demonstrated  formally
in  randomized  controlled  trials  using  long-term
functional  disability  as  the  primary  outcome.
• Other  new  approaches  are  currently  assessed  in
clinical  studies:
◦ using  the  diffusion-FLAIR  mismatch  or  penumbra
imaging  to  treat  some  patients  despite  wake-up
stroke,  or  beyond  the  4.5  hour  time  window,
◦ next-generation  thrombolytics,
◦ telestroke,
◦ pre-hospital  thrombolysis  using  a  mobile
neurovascular  unit,
◦ sonothrombolysis.isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
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